Loading...
HPV vaccines
Kang, Gagandeep
Kang, Gagandeep
Author(s)
Contributor(s)
Keywords
GE Subjects
Collections
Files
Loading...
n181ss56.pdf
Adobe PDF, 72.59 KB
Research Projects
Organizational Units
Journal Issue
Online Access
Abstract
"In 2008, Harald Zur Hausen received the Nobel Prize in physiology and medicine for showing that two human papilloma viruses, HPV16 and HPV18, were associated with the bulk of cervical cancers, and that some of the genes contained within the viruses were incorporated into the infected host tissue, resulting in carcinogenesis. These carcinogenic strains of HPV cause 70% of cervical cancer and kill an estimated 175,000 women annually. In 2006, the first HPV vaccine, Gardasil(r), made by Merck, was launched on the US market, as the “first anti-cancer” vaccine. Subsequently, a second HPV vaccine, Cervarix(r), has been released by GlaxoSmithKline. As with other pharmaceutical company products, both vaccines have been widely marketed and promoted by the companies. However, the marketing of these vaccines and the nature of the information and advocacy provided have led to concerns regarding the role of pharmaceutical companies in the dissemination of information relevant to consumer and public health decision making. In an article published in the JAMA, Rothman and Rothman have considered the marketing strategy for Gardasil(r) and its implications for medical professionals
Note(s)
Topic
Type
Article
Date
2010-01
Identifier
ISBN
DOI
Copyright/License
With permission of the license/copyright holder